Cancer Research Cancer Research Funding Available  Genetics and Biology of Brain Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 49, 4780-4784, September 1, 1989]
© 1989 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Brodie, A. M. H.
Right arrow Articles by Albrecht, E. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brodie, A. M. H.
Right arrow Articles by Albrecht, E. D.

Effect of Treatment with Aromatase Inhibitor 4-Hydroxandrostenedione on the Nonhuman Primate Menstrual Cycle1

Angela M. H. Brodie2, Janice O. Hammond, Maya Ghosh, Katherine Meyer and Eugene D. Albrecht

Departments of Pharmacology and Experimental Therapeutics [A. M. H. B., J. O. H., M. G., K. M.] and of Obstetrics and Gynecology [E. D. A.], School of Medicine, University of Maryland, Baltimore, Maryland 21201

4-Hydroxyandrostenedione (4-OHA) is a potent inhibitor of rat ovarian and human placental aromatase activity as assessed in vitro and has been shown to suppress ovarian estrogen secretion in vivo in rats. The compound inhibited extragonadal aromatization in male rhesus monkeys and reduced plasma levels of estradiol in postmenopausal women with advanced, metastatic breast cancer. Furthermore, 4-OHA caused disease remission in these patients. Prior to using this compound in premenopausal patients, the present study was carried out to determine whether 4-OHA affects the menstrual cycle by inhibiting ovarian estrogen production in nonhuman primate species. Four baboons (Papio anabis) exhibiting regular menstrual cycles were studied. Blood samples were collected daily throughout a control menstrual cycle and during treatment with daily s.c. injections of 4-OHA. Menstruation was not observed in three of four animals during treatment and did not resume until cessation of 4-OHA administration. The midcycle surge of estradiol which averaged 411 pg/ml in the control menstrual cycle was reduced during 4-OHA treatment by a mean of 49% of control. Thereafter, with continued 4-OHA treatment, serum concentrations of estradiol were significantly reduced below the basal control level [75.3 ± 5.6 (SE) pg/ml] and were very low or undetectable. Perineal turgescence, an index of estrogenicity, was inhibited by 4-OHA administration. The preovulatory surge of serum luteinizing hormone, which averaged 114 ng/ml during the control cycle, appeared normal in three of four animals following 12 to 14 days of 4-OHA administration, but no luteinizing hormone surge occurred with continued 4-OHA administration. The results indicate that, although 4-OHA reduces ovarian estrogen formation during the first cycle, treatment for a second consecutive cycle appears to be necessary for maximal suppression.

1 This work was supported by NIH Grant HD-13909 and presented in part at the 1986 Meeting of the Society for the Study of Reproduction and the Third International Congress on Hormones and Cancer, 1987.

2 To whom requests for reprints should be addressed, at Department of Pharmacology and Experimental Therapeutics, School of Medicine, University of Maryland, 655 W. Baltimore Street, Baltimore, MD 21201.

Received 3/25/88. Revised 3/ 9/89. Accepted 5/15/89.




This article has been cited by other articles:


Home page
Toxicol SciHome page
J. T. Sanderson, J. Hordijk, M. S. Denison, M. F. Springsteel, M. H. Nantz, and M. van den Berg
Induction and Inhibition of Aromatase (CYP19) Activity by Natural and Synthetic Flavonoid Compounds in H295R Human Adrenocortical Carcinoma Cells
Toxicol. Sci., November 1, 2004; 82(1): 70 - 79.
[Abstract] [Full Text] [PDF]


Home page
Toxicol PatholHome page
J. M. Cline, G. Soderqvist, T. C. Register, J. K. Williams, M. R. Adams, and B. Von Schoultz
Assessment of Hormonally Active Agents in the Reproductive Tract of Female Nonhuman Primates
Toxicol Pathol, January 1, 2001; 29(1): 84 - 90.
[Abstract] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
J. Nakamura, Q. Lu, G. Aberdeen, E. Albrecht, and A. Brodie
The Effect of Estrogen on Aromatase and Vascular Endothelial Growth Factor Messenger Ribonucleic Acid in the Normal Nonhuman Primate Mammary Gland
J. Clin. Endocrinol. Metab., April 1, 1999; 84(4): 1432 - 1437.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1989 by the American Association for Cancer Research.